Annual EBITDA
-$20.03 M
-$4.44 M-28.47%
December 31, 2023
Summary
- As of February 8, 2025, CYTH annual EBITDA is -$20.03 million, with the most recent change of -$4.44 million (-28.47%) on December 31, 2023.
- During the last 3 years, CYTH annual EBITDA has fallen by -$11.08 million (-123.87%).
- CYTH annual EBITDA is now -4214.79% below its all-time high of $486.80 thousand, reached on December 31, 2013.
Performance
CYTH EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$8.29 M
-$2.65 M-47.11%
September 30, 2024
Summary
- As of February 8, 2025, CYTH quarterly EBITDA is -$8.29 million, with the most recent change of -$2.65 million (-47.11%) on September 30, 2024.
- Over the past year, CYTH quarterly EBITDA has dropped by -$2.65 million (-47.00%).
- CYTH quarterly EBITDA is now -2149.79% below its all-time high of $404.30 thousand, reached on June 30, 2013.
Performance
CYTH Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$24.67 M
-$3.52 M-16.67%
September 30, 2024
Summary
- As of February 8, 2025, CYTH TTM EBITDA is -$24.67 million, with the most recent change of -$3.52 million (-16.67%) on September 30, 2024.
- Over the past year, CYTH TTM EBITDA has dropped by -$4.63 million (-23.14%).
- CYTH TTM EBITDA is now -3066.04% below its all-time high of $831.60 thousand, reached on June 30, 2013.
Performance
CYTH TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CYTH EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -28.5% | -47.0% | -23.1% |
| 3 y3 years | -123.9% | -47.0% | -23.1% |
| 5 y5 years | -371.9% | -47.0% | -23.1% |
CYTH EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -40.5% | at low | -199.5% | at low | -89.7% | at low |
| 5 y | 5-year | -171.2% | at low | -478.4% | at low | -234.0% | at low |
| alltime | all time | -4214.8% | at low | -2149.8% | at low | -3066.0% | at low |
Cyclo Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$8.29 M(+47.1%) | -$24.67 M(+16.7%) |
| Jun 2024 | - | -$5.63 M(+10.3%) | -$21.14 M(+5.0%) |
| Mar 2024 | - | -$5.11 M(-9.4%) | -$20.14 M(+0.5%) |
| Dec 2023 | -$20.03 M(+28.5%) | -$5.64 M(+18.4%) | -$20.03 M(+3.5%) |
| Sep 2023 | - | -$4.76 M(+2.9%) | -$19.36 M(+2.8%) |
| Jun 2023 | - | -$4.63 M(-7.5%) | -$18.84 M(+6.7%) |
| Mar 2023 | - | -$5.00 M(+0.7%) | -$17.66 M(+13.3%) |
| Dec 2022 | -$15.59 M(+9.4%) | -$4.97 M(+17.1%) | -$15.59 M(+16.4%) |
| Sep 2022 | - | -$4.24 M(+23.0%) | -$13.39 M(+3.0%) |
| Jun 2022 | - | -$3.45 M(+17.8%) | -$13.00 M(-1.1%) |
| Mar 2022 | - | -$2.93 M(+5.9%) | -$13.15 M(-7.7%) |
| Dec 2021 | -$14.25 M(+59.3%) | -$2.77 M(-28.2%) | -$14.25 M(+0.6%) |
| Sep 2021 | - | -$3.85 M(+7.2%) | -$14.16 M(+20.6%) |
| Jun 2021 | - | -$3.60 M(-10.9%) | -$11.74 M(+13.5%) |
| Mar 2021 | - | -$4.03 M(+50.6%) | -$10.34 M(+15.6%) |
| Dec 2020 | -$8.95 M(+21.2%) | -$2.68 M(+86.9%) | -$8.95 M(+2.2%) |
| Sep 2020 | - | -$1.43 M(-34.8%) | -$8.75 M(-2.2%) |
| Jun 2020 | - | -$2.20 M(-16.7%) | -$8.95 M(+10.2%) |
| Mar 2020 | - | -$2.64 M(+6.3%) | -$8.12 M(+9.9%) |
| Dec 2019 | -$7.39 M(+74.0%) | -$2.48 M(+52.6%) | -$7.39 M(+18.1%) |
| Sep 2019 | - | -$1.63 M(+18.9%) | -$6.26 M(+15.5%) |
| Jun 2019 | - | -$1.37 M(-28.2%) | -$5.42 M(+1.4%) |
| Mar 2019 | - | -$1.91 M(+40.9%) | -$5.34 M(+25.8%) |
| Dec 2018 | -$4.24 M(+10.8%) | -$1.35 M(+71.9%) | -$4.24 M(-0.6%) |
| Sep 2018 | - | -$787.20 K(-39.1%) | -$4.27 M(+3.7%) |
| Jun 2018 | - | -$1.29 M(+59.2%) | -$4.12 M(+12.7%) |
| Mar 2018 | - | -$811.90 K(-41.1%) | -$3.65 M(-4.9%) |
| Dec 2017 | -$3.83 M(-6.3%) | -$1.38 M(+117.3%) | -$3.84 M(+17.4%) |
| Sep 2017 | - | -$634.50 K(-23.4%) | -$3.27 M(-22.9%) |
| Jun 2017 | - | -$828.60 K(-17.1%) | -$4.24 M(-4.2%) |
| Mar 2017 | - | -$999.50 K(+23.4%) | -$4.43 M(+8.4%) |
| Dec 2016 | -$4.09 M(+83.2%) | -$810.10 K(-49.5%) | -$4.09 M(-1.8%) |
| Sep 2016 | - | -$1.60 M(+57.8%) | -$4.16 M(+27.9%) |
| Jun 2016 | - | -$1.02 M(+54.8%) | -$3.25 M(+27.6%) |
| Mar 2016 | - | -$657.00 K(-25.6%) | -$2.55 M(+14.2%) |
| Dec 2015 | -$2.23 M(+448.7%) | -$883.60 K(+27.1%) | -$2.23 M(+37.6%) |
| Sep 2015 | - | -$695.40 K(+122.2%) | -$1.62 M(+49.7%) |
| Jun 2015 | - | -$313.00 K(-7.7%) | -$1.08 M(+14.7%) |
| Mar 2015 | - | -$339.10 K(+23.8%) | -$943.90 K(+132.1%) |
| Dec 2014 | -$406.60 K(-183.5%) | -$273.80 K(+74.6%) | -$406.60 K(+101.6%) |
| Sep 2014 | - | -$156.80 K(-10.0%) | -$201.70 K(+90.1%) |
| Jun 2014 | - | -$174.20 K(-187.9%) | -$106.10 K(-122.5%) |
| Mar 2014 | - | $198.20 K(-387.7%) | $472.40 K(-3.0%) |
| Dec 2013 | $486.80 K(+60.3%) | -$68.90 K(+12.6%) | $486.80 K(-36.2%) |
| Sep 2013 | - | -$61.20 K(-115.1%) | $763.00 K(-8.2%) |
| Jun 2013 | - | $404.30 K(+90.2%) | $831.60 K(+108.6%) |
| Mar 2013 | - | $212.60 K(+2.6%) | $398.60 K(+31.3%) |
| Dec 2012 | $303.60 K | $207.30 K(+2701.4%) | $303.60 K(+555.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2012 | - | $7400.00(-125.8%) | $46.30 K(-5244.4%) |
| Jun 2012 | - | -$28.70 K(-124.4%) | -$900.00(-101.2%) |
| Mar 2012 | - | $117.60 K(-335.2%) | $76.90 K(-296.2%) |
| Dec 2011 | -$39.20 K(-408.7%) | -$50.00 K(+25.6%) | -$39.20 K(-146.0%) |
| Sep 2011 | - | -$39.80 K(-181.1%) | $85.20 K(-28.3%) |
| Jun 2011 | - | $49.10 K(+3173.3%) | $118.80 K(+18.2%) |
| Mar 2011 | - | $1500.00(-98.0%) | $100.50 K(+685.2%) |
| Dec 2010 | $12.70 K(-107.4%) | $74.40 K(-1300.0%) | $12.80 K(-105.9%) |
| Sep 2010 | - | -$6200.00(-120.1%) | -$218.80 K(+25.2%) |
| Jun 2010 | - | $30.80 K(-135.7%) | -$174.70 K(-17.8%) |
| Mar 2010 | - | -$86.20 K(-45.2%) | -$212.50 K(+21.0%) |
| Dec 2009 | -$172.60 K(-8.4%) | -$157.20 K(-514.8%) | -$175.60 K(+57.3%) |
| Sep 2009 | - | $37.90 K(-641.4%) | -$111.60 K(-26.8%) |
| Jun 2009 | - | -$7000.00(-85.8%) | -$152.40 K(-4.0%) |
| Mar 2009 | - | -$49.30 K(-47.1%) | -$158.80 K(-15.8%) |
| Dec 2008 | -$188.50 K(-186.5%) | -$93.20 K(+3113.8%) | -$188.50 K(+390.9%) |
| Sep 2008 | - | -$2900.00(-78.4%) | -$38.40 K(-211.3%) |
| Jun 2008 | - | -$13.40 K(-83.0%) | $34.50 K(-74.6%) |
| Mar 2008 | - | -$79.00 K(-238.8%) | $135.60 K(-37.8%) |
| Dec 2007 | $218.00 K(+132.2%) | $56.90 K(-18.7%) | $218.00 K(-15.2%) |
| Sep 2007 | - | $70.00 K(-20.2%) | $257.20 K(+63.9%) |
| Jun 2007 | - | $87.70 K(+2479.4%) | $156.90 K(+149.8%) |
| Mar 2007 | - | $3400.00(-96.5%) | $62.80 K(-33.1%) |
| Dec 2006 | $93.90 K(-221.0%) | $96.10 K(-417.2%) | $93.90 K(-310.5%) |
| Sep 2006 | - | -$30.30 K(+373.4%) | -$44.60 K(-44.3%) |
| Jun 2006 | - | -$6400.00(-118.6%) | -$80.10 K(+71.9%) |
| Mar 2006 | - | $34.50 K(-181.4%) | -$46.60 K(-39.9%) |
| Dec 2005 | -$77.60 K(-69.1%) | -$42.40 K(-35.6%) | -$77.60 K(-860.8%) |
| Sep 2005 | - | -$65.80 K(-342.8%) | $10.20 K(-88.7%) |
| Jun 2005 | - | $27.10 K(+674.3%) | $90.20 K(+19.3%) |
| Mar 2005 | - | $3500.00(-92.3%) | $75.60 K(+11.8%) |
| Dec 2004 | -$251.20 K(-376.3%) | $45.40 K(+219.7%) | $67.60 K(+53.3%) |
| Sep 2004 | - | $14.20 K(+13.6%) | $44.10 K(-34.9%) |
| Jun 2004 | - | $12.50 K(-377.8%) | $67.70 K(-22.3%) |
| Mar 2004 | - | -$4500.00(-120.5%) | $87.10 K(-4.2%) |
| Dec 2003 | $90.90 K(-59.0%) | $21.90 K(-42.1%) | $90.90 K(+87.8%) |
| Sep 2003 | - | $37.80 K(+18.5%) | $48.40 K(-49.1%) |
| Jun 2003 | - | $31.90 K(-4657.1%) | $95.10 K(-18.9%) |
| Mar 2003 | - | -$700.00(-96.6%) | $117.30 K(-47.0%) |
| Dec 2002 | $221.50 K(+702.5%) | -$20.60 K(-124.4%) | $221.50 K(-5.3%) |
| Sep 2002 | - | $84.50 K(+56.2%) | $234.00 K(+54.0%) |
| Jun 2002 | - | $54.10 K(-47.7%) | $151.90 K(+25.7%) |
| Mar 2002 | - | $103.50 K(-1377.8%) | $120.80 K(+336.1%) |
| Dec 2001 | $27.60 K(-141.8%) | -$8100.00(-437.5%) | $27.70 K(-153.4%) |
| Sep 2001 | - | $2400.00(-89.6%) | -$51.90 K(-23.5%) |
| Jun 2001 | - | $23.00 K(+121.2%) | -$67.80 K(-25.3%) |
| Mar 2001 | - | $10.40 K(-111.9%) | -$90.80 K(-10.3%) |
| Dec 2000 | -$66.00 K | -$87.70 K(+549.6%) | -$101.20 K(+649.6%) |
| Sep 2000 | - | -$13.50 K | -$13.50 K |
FAQ
- What is Cyclo Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Cyclo Therapeutics?
- What is Cyclo Therapeutics annual EBITDA year-on-year change?
- What is Cyclo Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Cyclo Therapeutics?
- What is Cyclo Therapeutics quarterly EBITDA year-on-year change?
- What is Cyclo Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Cyclo Therapeutics?
- What is Cyclo Therapeutics TTM EBITDA year-on-year change?
What is Cyclo Therapeutics annual EBITDA?
The current annual EBITDA of CYTH is -$20.03 M
What is the all time high annual EBITDA for Cyclo Therapeutics?
Cyclo Therapeutics all-time high annual EBITDA is $486.80 K
What is Cyclo Therapeutics annual EBITDA year-on-year change?
Over the past year, CYTH annual EBITDA has changed by -$4.44 M (-28.47%)
What is Cyclo Therapeutics quarterly EBITDA?
The current quarterly EBITDA of CYTH is -$8.29 M
What is the all time high quarterly EBITDA for Cyclo Therapeutics?
Cyclo Therapeutics all-time high quarterly EBITDA is $404.30 K
What is Cyclo Therapeutics quarterly EBITDA year-on-year change?
Over the past year, CYTH quarterly EBITDA has changed by -$2.65 M (-47.00%)
What is Cyclo Therapeutics TTM EBITDA?
The current TTM EBITDA of CYTH is -$24.67 M
What is the all time high TTM EBITDA for Cyclo Therapeutics?
Cyclo Therapeutics all-time high TTM EBITDA is $831.60 K
What is Cyclo Therapeutics TTM EBITDA year-on-year change?
Over the past year, CYTH TTM EBITDA has changed by -$4.63 M (-23.14%)